AU2007332878A1 - Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4, 3-b) indoles (variants), pharmacological means based thereon and method for the use thereof - Google Patents
Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4, 3-b) indoles (variants), pharmacological means based thereon and method for the use thereof Download PDFInfo
- Publication number
- AU2007332878A1 AU2007332878A1 AU2007332878A AU2007332878A AU2007332878A1 AU 2007332878 A1 AU2007332878 A1 AU 2007332878A1 AU 2007332878 A AU2007332878 A AU 2007332878A AU 2007332878 A AU2007332878 A AU 2007332878A AU 2007332878 A1 AU2007332878 A1 AU 2007332878A1
- Authority
- AU
- Australia
- Prior art keywords
- insult
- compound
- corresponds
- dimebon
- ischemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 29
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical class C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 14
- 230000000144 pharmacologic effect Effects 0.000 title claims description 10
- 230000002490 cerebral effect Effects 0.000 title description 11
- 230000004087 circulation Effects 0.000 title description 7
- 230000001154 acute effect Effects 0.000 title description 6
- 208000017667 Chronic Disease Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 120
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 24
- 230000001225 therapeutic effect Effects 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- ZRGIHRLCJVIUNZ-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-pyrido[4,3-b]indole Chemical compound N1=C2C=CC=CC2=C2C1CCNC2 ZRGIHRLCJVIUNZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008196 pharmacological composition Substances 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 description 63
- 230000000302 ischemic effect Effects 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 50
- 241000700159 Rattus Species 0.000 description 41
- 239000003814 drug Substances 0.000 description 31
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 24
- 229940079593 drug Drugs 0.000 description 24
- 229960000715 nimodipine Drugs 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 230000034994 death Effects 0.000 description 20
- 231100000517 death Toxicity 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 238000002648 combination therapy Methods 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 230000006378 damage Effects 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 208000014674 injury Diseases 0.000 description 15
- 230000007971 neurological deficit Effects 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 14
- 230000033001 locomotion Effects 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 12
- 239000012730 sustained-release form Substances 0.000 description 11
- 230000006735 deficit Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000028867 ischemia Diseases 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 201000006474 Brain Ischemia Diseases 0.000 description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 230000003920 cognitive function Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 210000001715 carotid artery Anatomy 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 102000003678 AMPA Receptors Human genes 0.000 description 5
- 108090000078 AMPA Receptors Proteins 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 208000007542 Paresis Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- CYJQCYXRNNCURD-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2C1CCN(C)C2 CYJQCYXRNNCURD-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000701 neuroleptic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101000953562 Dendroaspis angusticeps Kunitz-type serine protease inhibitor homolog calcicludine Proteins 0.000 description 3
- 101000723297 Dendroaspis polylepis polylepis Calciseptin Proteins 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- -1 dimebon Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 231100000861 limb weakness Toxicity 0.000 description 3
- 208000027905 limb weakness Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CYJQCYXRNNCURD-DGCLKSJQSA-N (4ar,9bs)-2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2[C@@H]2[C@H]1CCN(C)C2 CYJQCYXRNNCURD-DGCLKSJQSA-N 0.000 description 2
- JIHMATXQZDSUOR-UHFFFAOYSA-N 2,3,4,4a,5,5a-hexahydro-1h-pyrido[4,3-b]indole Chemical compound N1C2C=CC=CC2=C2C1CCNC2 JIHMATXQZDSUOR-UHFFFAOYSA-N 0.000 description 2
- BPPMRCNUQCVVFJ-UHFFFAOYSA-N 2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical class N1C2=CC=CC=C2C2C1CCNC2 BPPMRCNUQCVVFJ-UHFFFAOYSA-N 0.000 description 2
- IKMNOGHPKNFPTK-UHFFFAOYSA-N 2-ethyl-6-methylpyridin-1-ium-3-ol;4-hydroxy-4-oxobutanoate Chemical compound OC(=O)CCC(O)=O.CCC1=NC(C)=CC=C1O IKMNOGHPKNFPTK-UHFFFAOYSA-N 0.000 description 2
- WCTGYFWVYBPRGF-UHFFFAOYSA-N 8-chloro-2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CCC1=CC=C(C)N=C1 WCTGYFWVYBPRGF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- CJUOSBUQOWKEKJ-UHFFFAOYSA-N Mebhydrolin napadisilate Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 CJUOSBUQOWKEKJ-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010027925 Monoparesis Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010044522 Traumatic haematoma Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960004788 choline alfoscerate Drugs 0.000 description 2
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 2
- 229960000876 cinnarizine Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229950010754 dicarbine Drugs 0.000 description 2
- 229950000904 dorastine Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940125384 geroprotector Drugs 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 229960003642 nicergoline Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 208000012318 pareses Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 150000008591 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles Chemical class 0.000 description 1
- RPROHCOBMVQVIV-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole Chemical class N1C2=CC=CC=C2C2=C1CCNC2 RPROHCOBMVQVIV-UHFFFAOYSA-N 0.000 description 1
- MUZFLDUALLSEBH-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2=C1CCN(C)C2 MUZFLDUALLSEBH-UHFFFAOYSA-N 0.000 description 1
- XWLFAMANDIWUKH-UHFFFAOYSA-N 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole-2,5-diium;dichloride Chemical compound Cl.Cl.N1C2=CC=C(C)C=C2C2C1CCN(C)C2 XWLFAMANDIWUKH-UHFFFAOYSA-N 0.000 description 1
- TWZCZLLZJDKWFN-UHFFFAOYSA-N 2-benzyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound C1CC=2NC3=CC=CC=C3C=2CN1CC1=CC=CC=C1 TWZCZLLZJDKWFN-UHFFFAOYSA-N 0.000 description 1
- MYUAGMGKBGUWEN-UHFFFAOYSA-N 2-ethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(CC)C2 MYUAGMGKBGUWEN-UHFFFAOYSA-N 0.000 description 1
- FYHWPFXPFFPQRT-UHFFFAOYSA-N 2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(C)C2 FYHWPFXPFFPQRT-UHFFFAOYSA-N 0.000 description 1
- UPLUVROGBHSYKI-UHFFFAOYSA-N 2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CCC1=CC=C(C)N=C1 UPLUVROGBHSYKI-UHFFFAOYSA-N 0.000 description 1
- NGNVOGPUTBVHTL-UHFFFAOYSA-N 5-benzyl-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1=CC=CC=C1 NGNVOGPUTBVHTL-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000010248 Cerebrovascular Trauma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229940127505 Sodium Channel Antagonists Drugs 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 1
- 229960004934 mebhydrolin Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000004466 pelleted feed Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 208000020861 perceptual disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000010926 vascular brain injury Diseases 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2006143332 | 2006-12-07 | ||
| RU2006143332/15A RU2340342C2 (ru) | 2006-12-07 | 2006-12-07 | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| PCT/US2007/024626 WO2008073231A1 (en) | 2006-12-07 | 2007-11-30 | Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4, 3-b) indoles (variants), pharmacological means based thereon and method for the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007332878A1 true AU2007332878A1 (en) | 2008-06-19 |
Family
ID=39512028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007332878A Abandoned AU2007332878A1 (en) | 2006-12-07 | 2007-11-30 | Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4, 3-b) indoles (variants), pharmacological means based thereon and method for the use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110112132A1 (OSRAM) |
| EP (1) | EP2101578A4 (OSRAM) |
| JP (1) | JP2010511701A (OSRAM) |
| AU (1) | AU2007332878A1 (OSRAM) |
| CA (1) | CA2671569A1 (OSRAM) |
| RU (1) | RU2340342C2 (OSRAM) |
| WO (1) | WO2008073231A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010540439A (ja) | 2007-09-20 | 2010-12-24 | ディー２イー，エルエルシー | 神経保護性の及び認知を向上させる性質を備えた水素化されたピリド［４，３−ｂ］インドール類のフッ素を含有する誘導体、調製するための工程、並びに使用 |
| RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP2280968A2 (en) | 2008-03-24 | 2011-02-09 | Medivation Technologies, Inc. | Pyrido [3, 4-b]indoles and methods of use |
| PE20091820A1 (es) | 2008-03-24 | 2009-12-10 | Medivation Technologies Inc | Compuestos heterociclicos con uniones puente y metodos para usarlos |
| JP5551708B2 (ja) | 2008-10-31 | 2014-07-16 | メディベイション テクノロジーズ， インコーポレイテッド | アゼピノ［４，５−ｂ］インドール化合物およびその使用方法 |
| US8907097B2 (en) | 2008-10-31 | 2014-12-09 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
| KR20110132564A (ko) | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| EP2424364A4 (en) | 2009-04-29 | 2012-12-19 | Medivation Technologies Inc | PYRIDO [4.3-B] INDOLES AND METHODS OF USE |
| US8741919B2 (en) | 2009-04-29 | 2014-06-03 | Medivation Technologies, Inc. | Pyrido[4,3-B]indoles and methods of use |
| CA2775328A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| WO2011038163A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
| BR112012006648A2 (pt) | 2009-09-23 | 2019-09-24 | Medivation Neurology Inc | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9199985B2 (en) | 2011-02-18 | 2015-12-01 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| WO2012154261A1 (en) | 2011-02-18 | 2012-11-15 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| RU2477131C1 (ru) * | 2012-01-17 | 2013-03-10 | Алиса Владимировна Алесенко | СРЕДСТВО ДЛЯ НЕЙТРАЛИЗАЦИИ ТОКСИЧЕСКОГО ДЕЙСТВИЯ ФАКТОРА НЕКРОЗА ОПУХОЛИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ, ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ НА ОСНОВЕ НЕЙТРАЛИЗАЦИИ ТОКСИЧЕСКОГО ДЕЙСТВИЯ ФАКТОРА НЕКРОЗА ОПУХОЛИ |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2157671A1 (en) * | 1993-03-08 | 1994-09-15 | Kiyotaka Katsuta | Medicament for treating or preventing cerebrovascular diseases |
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| RU2283108C2 (ru) * | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
-
2006
- 2006-12-07 RU RU2006143332/15A patent/RU2340342C2/ru not_active IP Right Cessation
-
2007
- 2007-11-30 US US12/518,090 patent/US20110112132A1/en not_active Abandoned
- 2007-11-30 WO PCT/US2007/024626 patent/WO2008073231A1/en not_active Ceased
- 2007-11-30 CA CA002671569A patent/CA2671569A1/en not_active Abandoned
- 2007-11-30 EP EP07867589A patent/EP2101578A4/en not_active Withdrawn
- 2007-11-30 JP JP2009540237A patent/JP2010511701A/ja active Pending
- 2007-11-30 AU AU2007332878A patent/AU2007332878A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2671569A1 (en) | 2008-06-19 |
| RU2340342C2 (ru) | 2008-12-10 |
| WO2008073231A1 (en) | 2008-06-19 |
| EP2101578A4 (en) | 2012-09-05 |
| JP2010511701A (ja) | 2010-04-15 |
| US20110112132A1 (en) | 2011-05-12 |
| EP2101578A1 (en) | 2009-09-23 |
| RU2006143332A (ru) | 2008-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110112132A1 (en) | Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof | |
| JP6208235B2 (ja) | 多発性硬化症治療のためのビオチンの使用 | |
| ES3001196T3 (es) | Nuevo uso de una combinación de un bloqueador del receptor de la angiotensina (ARB) con un inhibidor de la endopeptidasa neutra (NEPI) | |
| AU2007328323A1 (en) | Means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof | |
| JP2012505257A (ja) | 多発性硬化症治療のための組成物および方法 | |
| MX2012007941A (es) | Farmaceutico para impedir o tratar alteraciones acompañadas por angiogenesis ocular y/o permeabilidad vascular ocular elevada. | |
| US20240016790A1 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| CA2899602A1 (en) | Pharmaceutical uses of inorganic nitrites | |
| MX2012001814A (es) | Uso de 4-aminopiridina para mejorar la discapacidad neuro - cognoscitiva y/o neuro - psiquiatrica en pacientes con condiciones desmielizantes y otras condiciones del sistema nervioso. | |
| US20020077355A1 (en) | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions | |
| US20120122919A1 (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| JP2006516629A (ja) | 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法 | |
| EP4193995A1 (en) | Use of btk inhibitors in the treatment of diseases | |
| KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| US20020055458A1 (en) | Method for the prevention and treatment of retinopathy | |
| MD4522143T2 (ro) | Tratamentul durerii asociate cu sensibilizare centrală | |
| KR20150058159A (ko) | 바클로펜 및 아캄프로세이트 기반 황반 변성 장애의 치료 | |
| US20090118264A1 (en) | Medicament having neovascularization promoting action | |
| EP4110396A1 (en) | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia | |
| CA3170508C (en) | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia | |
| WO2014087231A2 (ru) | Фармацевтическая композиция, обладающая нейропротекторным, ноотропным, антиамнестическим действием, и способ профилактики и/или лечения состояний, связанных с нарушением мозгового кровообращения, цереброваскулярных и нейродегенеративных заболеваний | |
| EP1795193B1 (en) | Histidine for suppressing brain tissue necrosis attributed to long-time ischemia | |
| RU2772278C2 (ru) | Лечение мигрени | |
| TW201806601A (zh) | σ受體配體在皰疹後遺疼痛中的用途 | |
| AB | ARTHROTEX f |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |